May 7, 2008 - GenVec, Inc. (Nasdaq:GNVC) announced today that it has received an Advanced Technology Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases, of the National Institutes of Health, to support the Company’s efforts to develop vaccines for the prevention of respiratory syncytial virus (RSV). The SBIR grant, valued at $600,000 over two years, will support work being conducted exclusively at GenVec... GenVec's Press Release -
Showing posts with label GenVec. Show all posts
Showing posts with label GenVec. Show all posts
May 15, 2008
GenVec : Grant for RSV Vaccine Program
May 7, 2008 - GenVec, Inc. (Nasdaq:GNVC) announced today that it has received an Advanced Technology Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases, of the National Institutes of Health, to support the Company’s efforts to develop vaccines for the prevention of respiratory syncytial virus (RSV). The SBIR grant, valued at $600,000 over two years, will support work being conducted exclusively at GenVec... GenVec's Press Release -
Subscribe to:
Posts (Atom)
